LEADER 05818nam 2201501z- 450 001 9910557544303321 005 20220111 035 $a(CKB)5400000000044164 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76594 035 $a(oapen)doab76594 035 $a(EXLCZ)995400000000044164 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPreclinical Evaluation of Lipid-Based Nanosystems 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (351 p.) 311 08$a3-0365-1550-X 311 08$a3-0365-1549-6 330 $aThe use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. For instance, they can increase the targeting and bioavailability of drugs, improving therapeutic effects. Their use in the cosmetic field is also promising, owing to their moisturizing properties and ability to protect labile cosmetic actives. Thus, it is surprising that only a few lipid-based nanosystems have reached the market. This can be explained by the strict regulatory requirements of medicines and the occurrence of unexpected in vivo failure, which highlights the need to conduct more preclinical studies.Current research is focused on testing the in vitro, ex vivo, and in vivo efficacy of lipid-based nanosystems to predict their clinical performance. However, there is a lack of method validation, which compromises the comparison between different studies.This book brings together the latest research and reviews that report on in vitro, ex vivo, and in vivo preclinical studies using lipid-based nanosystems. Readers can find up-to-date information on the most common experiments performed to predict the clinical behavior of lipid-based nanosystems. A series of 15 research articles and a review are presented, with authors from 15 different countries, which demonstrates the universality of the investigations that have been carried out in this area. 606 $aTechnology: general issues$2bicssc 610 $aacoustic response 610 $aalopecia areata 610 $aammonia 610 $aatopic dermatitis 610 $abiocorona 610 $abiodistribution 610 $aBox?Behnken design 610 $abreast cancer 610 $aCaco-2 monolayer 610 $acancer 610 $acholesterol 610 $aclarithromycin 610 $acolon cancer therapy 610 $acyanocobalamin 610 $aD-optimal design 610 $adexamethasone 610 $adialysis 610 $adissolution enhancement 610 $adocohexaenoic acid 610 $aDoE 610 $adoxorubicin 610 $adrug delivery 610 $adrug release 610 $aefavirenz 610 $aethyl cellulose 610 $aex vivo permeation 610 $afenofibrate 610 $aflaxseed oil 610 $afluconazole 610 $afollicular targeting 610 $aformulation optimization 610 $aFZD10 protein 610 $ahyaluronic acid 610 $ahydrophobic ion pairing 610 $aintestinal permeation enhancers 610 $aintoxication 610 $aligand distribution 610 $alight activation 610 $alipid phase 610 $alipid polymer hybrid nanocapsules 610 $alipid vesicles 610 $alipid-based formulation 610 $alipolysis 610 $alipomers 610 $aliposome 610 $aliposomes 610 $amelanoma 610 $amesoporous silica 610 $amicrobubble 610 $amobility 610 $aN-alkylisatin 610 $an/a 610 $ananocarrier 610 $ananoemulsion(s) 610 $ananomedicine 610 $ananostructured lipid carriers 610 $ananostructured lipid carriers (NLC) 610 $ananotransfersome 610 $anasal route 610 $aneuroinflammation 610 $aneuroprotection 610 $anon-ionic surfactants 610 $anose-to-brain 610 $aoligonucleotide 610 $aoptimization 610 $aoral drug delivery 610 $aPAI-2 610 $apermeation 610 $apharmacokinetics 610 $aphase-behavior 610 $aphospholipid coating 610 $aphospholipids 610 $aporous microparticles 610 $apsoriasis 610 $aquality by design (QbD) 610 $arheological behavior 610 $arivastigmine 610 $aself-emulsifying drug delivery systems 610 $aSerpinB2 610 $asilica-lipid hybrid 610 $askin 610 $askin topical delivery 610 $asolid dosage forms 610 $asolid lipid nanoparticles 610 $aspray drying 610 $astability 610 $asupersaturation 610 $atarget delivery nanosystem 610 $atransferosomes 610 $aulcer index 610 $aultrasound contrast agents 610 $aurokinase plasminogen activator 610 $avegetable oils 610 $avitamin B12 610 $azone of inhibition 615 7$aTechnology: general issues 700 $aSilva$b Ana Catarina$4edt$01301848 702 $aSousa Lobo$b Jose? Manuel$4edt 702 $aSilva$b Ana Catarina$4oth 702 $aSousa Lobo$b Jose? Manuel$4oth 906 $aBOOK 912 $a9910557544303321 996 $aPreclinical Evaluation of Lipid-Based Nanosystems$93030940 997 $aUNINA